Compare Equinor ASA (EQNR) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Novavax Inc — how do they compare? Equinor ASA trades at $35.58 (market cap $82.75B), while Novavax Inc trades at $8.22 (market cap $1.39B). The key difference: Equinor ASA is far larger — about 59.5× Novavax Inc's market cap, and Equinor ASA pays a 4.24% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| EQNR | NVAX | |
|---|---|---|
Market Cap | $82.75B | $1.39B |
Sector | Energy | Health |
52-Week High | $42.40 | $11.19 |
52-Week Low | $22.41 | $6.22 |
Enterprise Value | $94.51B | $890.94M |
Dividend Yield | 4.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $35.78, down 1.13% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed recent earnings, beating expectations in Q1 2026 but missing in Q3 2025. Recent news highlights strategic investments in Norwegian Continental Shelf projects and a share buy-back program, while exiting non-core operations like Japan offshore wind.
EQNR presents a moderate investment case with a low P/E of 16.23 and strong cash flow, but faces risks from declining net income margins and volatile energy markets. Analyst sentiment is mixed with a 30% buy rating, suggesting cautious optimism amid execution and commodity price uncertainties.
Novavax (NVAX) trades at $8.21, down 2.49% amid bearish technical signals and negative cash flow trends. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 and three consecutive earnings beats, but faces profitability challenges with negative net income margin and ROE. Recent news highlights shareholder dissent and underperformance versus broader market trends, while analyst consensus remains bullish with a $14 price target representing 70% upside potential.
The outlook balances significant upside potential against substantial execution risks. Positive catalysts include consistent earnings beats and strong analyst support, but concerns persist around cash burn, negative equity, and competitive vaccine market pressures. Investors face volatility from operational challenges despite attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
